Prognostic gene expression signature for high-grade serous ovarian cancer
- Millstein, J
- Budden, T
- Goode, E L
- Anglesio, M S
- Talhouk, A
- Intermaggio, M P
- Leong, H S
- Chen, S
- Elatre, W
- Gilks, B
- Nazeran, T
- Volchek, M
- Bentley, R C
- Wang, C
- Chiu, D S
- Kommoss, S
- Leung, S C Y
- Senz, J
- Lum, A
- Chow, V
- Sudderuddin, H
- Mackenzie, R
- George, J
- Fereday, S
- Hendley, J
- Traficante, N
- Steed, H
- Koziak, J M
- Köbel, M
- Mcneish, I.A.
- Goranova, T
- Ennis, D.
- Macintyre, G
- Silva, D
- Ramón Y Cajal, T
- García-Donas, J
- Polo, S Hernando
- Rodriguez, G C
- Cushing-Haugen, K L
- Harris, H R
- Greene, C S
- Zelaya, R A
- Behrens, S
- Fortner, R T
- Sinn, P
- Herpel, E
- Lester, J
- Lubiński, J
- Oszurek, O
- Tołoczko, A
- Cybulski, C
- Menkiszak, J
- Pearce, C L
- Pike, M C
- Tseng, C
- Alsop, J
- Rhenius, V
- Song, H
- Jimenez-Linan, M
- Piskorz, A
- Gentry-Maharaj, A
- Karpinskyj, C
- Widschwendter, M
- Singh, N
- Kennedy, C J
- Sharma, R
- Harnett, P R
- Gao, B
- Johnatty, S E
- Sayer, R
- Boros, J
- Winham, S J
- Keeney, G L
- Kaufmann, S H
- Larson, M C
- Luk, H
- Hernandez, B Y
- Thompson, P J
- Wilkens, L R
- Carney, M E
- Trabert, B
- Lissowska, J
- Brinton, L
- Sherman, M E
- Bodelon, C
- Hinsley, S.
- Lewsley, L.A.
- Glasspool, R.
- Banerjee, S N
- Stronach, E A
- Haluska, P
- Ray-Coquard, I
- Mahner, S
- Winterhoff, B
- Slamon, D
- Levine, D A
- Kelemen, L E
- Benitez, J
- Chang-Claude, J
- Gronwald, J
- Wu, A H
- Menon, U
- Goodman, M T
- Schildkraut, J M
- Wentzensen, N
- Brown, R
- Berchuck, A
- Chenevix-Trench, G
- deFazio, A
- Gayther, S A
- García, M J
- Henderson, M
- Rossing, M A
- Beeghly-Fadiel, A
- Fasching, P A
- Orsulic, S
- Karlan, B Y
- Konecny, G E
- Huntsman, D G
- Bowtell, D D
- Brenton, J D
- Doherty, J A
- Pharoah, P D P
- Ramus, S J
DOIAbstract
BACKGROUND:Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS:Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies ...
Add to ORKG